Takeaways: This notice of allowance shores up Anixa’s IP moat around its AMHR2‑targeted ovarian cancer vaccine and aligns Canada with its existing US patent protection. ...
For decades, oncology innovation has focused primarily on developing more effective treatments for advanced disease. Today, however, the industry is beginning to shift toward a new frontier: detecting...
